Peregrine, Stason Pharmaceuticals Inc. deal

Peregrine granted Stason exclusive rights to develop and commercialize its tumor necrosis therapy (TNT) technologies in certain Asia-Pacific Economic Cooperation (APEC) countries. The deal includes exclusive rights to Cotara, an Iodine 131 radiolabelled chimeric tumor necrosis therapy (TNT) antibody that binds a DNA/histone complex in Phase II testing to treat glioblastoma multiforme (GBM); exclusive rights to the NHS76 TNT antibody, a human antibody that binds to DNA and histone-DNA complexes; and non-exclusive licenses for Peregrine's radiolabelling technologies. ...